Professor Cai-Cun Zhou: KRAS G12D Inhibitor HRS-4642 Shows Encouraging Activity in Late-Stage Solid Tumors with KRAS G12D Mutation

Professor Cai-Cun Zhou: KRAS G12D Inhibitor HRS-4642 Shows Encouraging Activity in Late-Stage Solid Tumors with KRAS G12D Mutation

The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Tumor Insight team delved into the front lines, capturing international advancements and witnessing China's contributions to the field of oncology on the global stage. Professor Cai-Cun Zhou from Tongji University Affiliated Shanghai Pulmonary Hospital delivered an important oral presentation at this conference (Abstract No: LBA33). In a live interview with "Tumor Insight," Professor Zhou shared insights into the research on the novel KRAS G12D inhibitor HRS-4642 for the treatment of late-stage solid tumor patients with KRAS G12D mutation, as well as thoughts and perspectives on the future direction of drug development. This article summarizes the relevant content for readers.
ESMO Big Shot Interview | Professor Xu Ruihua: Oncology in China Is Thriving, with a Record Number of Selected Papers

ESMO Big Shot Interview | Professor Xu Ruihua: Oncology in China Is Thriving, with a Record Number of Selected Papers

The 2023 European Society for Medical Oncology (ESMO) Annual Congress was held in Madrid, Spain from October 20th to 24th. The Oncology Horizon team went deep into the front lines, capturing international advancements and witnessing the progress of cancer research in China on the global stage. Professor Xu Ruihua from Sun Yat-sen University Cancer Center delivered a significant oral presentation at this year's congress. In an interview with "Oncology Horizon," Professor Xu shared highlights from the field of gastrointestinal oncology at ESMO and provided insights into the congress. This article compiles relevant content for our readers.
“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

Breast cancer is the most common malignancy among women globally, with an increasing incidence rate that poses a significant threat to women's health worldwide. Molecular typing aids in the precise classification and stratified treatment of breast cancer. The continuous development of immunotherapy and targeted therapy offers new treatment options for patients with different types. At the recent 2023 China Conference of Integrated Oncology (CCHIO 2023), "Tumor Watch" had the opportunity to interview Professor Zhang Jin from Tianjin Medical University Cancer Hospital at the venue. Professor Zhang discussed the current state of breast cancer research in China, reviewed the evolution of breast cancer treatment strategies, and shared insights into the precision treatment of patients with different types.
ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

At this year's recently concluded ESMO conference, new developments related to the PARP inhibitor talazoparib in precision diagnosis and treatment were announced. Precision diagnosis has become a leading trend in the field of prostate cancer, and biomarker research is receiving increasing attention. In this context, this publication invited Professor Zhang Guiming from Qingdao University Affiliated Hospital, a well-known young expert in the field of prostate cancer, for an in-depth interview to explain the three new developments related to talazoparib's precision treatment recently announced at ESMO. Here, we provide a summary of the interview for the readers.
ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation

ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation

ESMO ASIA 2023 inaugurated its opening session, heralding a landmark event in the world of oncology. Hosted in the prestigious Hall 406, this congress brings together the brightest minds in cancer research and treatment, uniting a global community in the fight against this challenging disease. The opening ceremony featured the traditional Dragon Dance, symbolizing prosperity and health. This cultural performance underscored the congress's commitment to diversity and inclusivity, setting a vibrant tone for the event. After the opening address, ESMO also commended society in Asia for their outstanding contributions in promoting international cooperation and exchanges. Dr. Donglu Zhao accepted the certificate of appreciation on behalf of the Chinese Society of Clinical Oncology (CSCO).
ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition, ESMO 2023 also reported TAR201 and EV-302 study. Dr. Andrea Nccchi shared his views on these latest studies in an interview with " Oncology Frontier ".
ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled several advancements in prostate cancer research, extending the survival prospects for patients. Although there were some negative results, the research still holds positive significance. "Oncology Frontier" has specially invited Professor Yao Zhu from Fudan University's affiliated Cancer Hospital to provide an in-depth interpretation of these research developments.